Tracing IgE-Producing Cells in Allergic Patients
Immunoglobulin E (IgE) is the key immunoglobulin in the pathogenesis of IgE associated allergic diseases affecting 30% of the world population. Recent data suggest that allergen-specific IgE levels in serum of allergic patients are sustained by two different mechanisms: inducible IgE production thro...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-08-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/8/9/994 |
| _version_ | 1797765402178093056 |
|---|---|
| author | Julia Eckl-Dorna Sergio Villazala-Merino Nicholas James Campion Maria Byazrova Alexander Filatov Dmitry Kudlay Antonina Karsonova Ksenja Riabova Musa Khaitov Alexander Karaulov Verena Niederberger-Leppin Rudolf Valenta |
| author_facet | Julia Eckl-Dorna Sergio Villazala-Merino Nicholas James Campion Maria Byazrova Alexander Filatov Dmitry Kudlay Antonina Karsonova Ksenja Riabova Musa Khaitov Alexander Karaulov Verena Niederberger-Leppin Rudolf Valenta |
| author_sort | Julia Eckl-Dorna |
| collection | DOAJ |
| description | Immunoglobulin E (IgE) is the key immunoglobulin in the pathogenesis of IgE associated allergic diseases affecting 30% of the world population. Recent data suggest that allergen-specific IgE levels in serum of allergic patients are sustained by two different mechanisms: inducible IgE production through allergen exposure, and continuous IgE production occurring even in the absence of allergen stimulus that maintains IgE levels. This assumption is supported by two observations. First, allergen exposure induces transient increases of systemic IgE production. Second, reduction in IgE levels upon depletion of IgE from the blood of allergic patients using immunoapheresis is only temporary and IgE levels quickly return to pre-treatment levels even in the absence of allergen exposure. Though IgE production has been observed in the peripheral blood and locally in various human tissues (e.g., nose, lung, spleen, bone marrow), the origin and main sites of IgE production in humans remain unknown. Furthermore, IgE-producing cells in humans have yet to be fully characterized. Capturing IgE-producing cells is challenging not only because current staining technologies are inadequate, but also because the cells are rare, they are difficult to discriminate from cells bearing IgE bound to IgE-receptors, and plasma cells express little IgE on their surface. However, due to the central role in mediating both the early and late phases of allergy, free IgE, IgE-bearing effector cells and IgE-producing cells are important therapeutic targets. Here, we discuss current knowledge and unanswered questions regarding IgE production in allergic patients as well as possible therapeutic approaches targeting IgE. |
| first_indexed | 2024-03-12T20:10:39Z |
| format | Article |
| id | doaj.art-65245635249c40eeb26b21c7bd3bfe77 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-12T20:10:39Z |
| publishDate | 2019-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-65245635249c40eeb26b21c7bd3bfe772023-08-02T01:44:21ZengMDPI AGCells2073-44092019-08-018999410.3390/cells8090994cells8090994Tracing IgE-Producing Cells in Allergic PatientsJulia Eckl-Dorna0Sergio Villazala-Merino1Nicholas James Campion2Maria Byazrova3Alexander Filatov4Dmitry Kudlay5Antonina Karsonova6Ksenja Riabova7Musa Khaitov8Alexander Karaulov9Verena Niederberger-Leppin10Rudolf Valenta11Department of Otorhinolaryngology, Medical University of Vienna, Vienna A-1090, AustriaDepartment of Otorhinolaryngology, Medical University of Vienna, Vienna A-1090, AustriaDepartment of Otorhinolaryngology, Medical University of Vienna, Vienna A-1090, AustriaNRC Institute of Immunology FMBA of Russia, Moscow 115478, RussiaNRC Institute of Immunology FMBA of Russia, Moscow 115478, RussiaNRC Institute of Immunology FMBA of Russia, Moscow 115478, RussiaDepartment of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow 119435, RussiaDepartment of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow 119435, RussiaNRC Institute of Immunology FMBA of Russia, Moscow 115478, RussiaDepartment of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow 119435, RussiaDepartment of Otorhinolaryngology, Medical University of Vienna, Vienna A-1090, AustriaNRC Institute of Immunology FMBA of Russia, Moscow 115478, RussiaImmunoglobulin E (IgE) is the key immunoglobulin in the pathogenesis of IgE associated allergic diseases affecting 30% of the world population. Recent data suggest that allergen-specific IgE levels in serum of allergic patients are sustained by two different mechanisms: inducible IgE production through allergen exposure, and continuous IgE production occurring even in the absence of allergen stimulus that maintains IgE levels. This assumption is supported by two observations. First, allergen exposure induces transient increases of systemic IgE production. Second, reduction in IgE levels upon depletion of IgE from the blood of allergic patients using immunoapheresis is only temporary and IgE levels quickly return to pre-treatment levels even in the absence of allergen exposure. Though IgE production has been observed in the peripheral blood and locally in various human tissues (e.g., nose, lung, spleen, bone marrow), the origin and main sites of IgE production in humans remain unknown. Furthermore, IgE-producing cells in humans have yet to be fully characterized. Capturing IgE-producing cells is challenging not only because current staining technologies are inadequate, but also because the cells are rare, they are difficult to discriminate from cells bearing IgE bound to IgE-receptors, and plasma cells express little IgE on their surface. However, due to the central role in mediating both the early and late phases of allergy, free IgE, IgE-bearing effector cells and IgE-producing cells are important therapeutic targets. Here, we discuss current knowledge and unanswered questions regarding IgE production in allergic patients as well as possible therapeutic approaches targeting IgE.https://www.mdpi.com/2073-4409/8/9/994allergyIgEhumanmouseCD23FcεRIB cellT celltracingtargetingtherapy |
| spellingShingle | Julia Eckl-Dorna Sergio Villazala-Merino Nicholas James Campion Maria Byazrova Alexander Filatov Dmitry Kudlay Antonina Karsonova Ksenja Riabova Musa Khaitov Alexander Karaulov Verena Niederberger-Leppin Rudolf Valenta Tracing IgE-Producing Cells in Allergic Patients Cells allergy IgE human mouse CD23 FcεRI B cell T cell tracing targeting therapy |
| title | Tracing IgE-Producing Cells in Allergic Patients |
| title_full | Tracing IgE-Producing Cells in Allergic Patients |
| title_fullStr | Tracing IgE-Producing Cells in Allergic Patients |
| title_full_unstemmed | Tracing IgE-Producing Cells in Allergic Patients |
| title_short | Tracing IgE-Producing Cells in Allergic Patients |
| title_sort | tracing ige producing cells in allergic patients |
| topic | allergy IgE human mouse CD23 FcεRI B cell T cell tracing targeting therapy |
| url | https://www.mdpi.com/2073-4409/8/9/994 |
| work_keys_str_mv | AT juliaeckldorna tracingigeproducingcellsinallergicpatients AT sergiovillazalamerino tracingigeproducingcellsinallergicpatients AT nicholasjamescampion tracingigeproducingcellsinallergicpatients AT mariabyazrova tracingigeproducingcellsinallergicpatients AT alexanderfilatov tracingigeproducingcellsinallergicpatients AT dmitrykudlay tracingigeproducingcellsinallergicpatients AT antoninakarsonova tracingigeproducingcellsinallergicpatients AT ksenjariabova tracingigeproducingcellsinallergicpatients AT musakhaitov tracingigeproducingcellsinallergicpatients AT alexanderkaraulov tracingigeproducingcellsinallergicpatients AT verenaniederbergerleppin tracingigeproducingcellsinallergicpatients AT rudolfvalenta tracingigeproducingcellsinallergicpatients |